Why MedWatch Still Matters in the Age of Digital Safety Platforms

FDA says MedWatch is its program for reporting serious reactions, product quality problems, therapeutic inequivalence or failure, and product-use errors for human medical products, including drugs, biologics, devices, dietary supplements, infant formula, and cosmetics. The agency also says MedWatch receives reports from the public and, when appropriate, publishes safety alerts for FDA-regulated products.

That means AEMS does not make MedWatch irrelevant. Instead, the two sit at different but connected points in the safety ecosystem: MedWatch remains a recognizable front-end route for reporting and alerts, while AEMS represents a broader backend modernization of surveillance and data integration. This relationship is a reasonable inference from FDA’s descriptions of the two programs.

For PV professionals, the lesson is simple. Digital transformation in safety does not always replace legacy programs outright. Sometimes it repositions them within a larger system.